Atlas Trials

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

Clinical trial NCT03653052 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03653052
Sponsor
Simon C Pacey, MD
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Oesophageal Cancer
Start date
2018-10-30
Primary completion
2021-11-11
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.